文献速递造血干细胞移植与细胞治疗淋巴瘤

成人替代供者造血干细胞移植后的复合GRFS与CRFS结局

Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.
PubMed 文献 · J Clin Oncol · 2020-05-04

该注册回顾性分析纳入2198例接受脐血、单倍体、7/8骨髓或7/8外周血移植的成人患者,比较无GVHD无复发生存(GRFS)和无慢性GVHD无复发生存(CRFS)。多变量分析中单倍体组GRFS、CRFS和OS均最佳;清髓预处理下脐血、7/8骨髓及联合血清治疗的7/8外周血组间无差异,而7/8外周血未联合血清治疗组结局较差。

要点

  • 单倍体组在全部组中GRFS、CRFS和总生存均最佳。
  • 清髓预处理下脐血、7/8骨髓及联合血清治疗的7/8外周血组GRFS和CRFS无差异。
  • 减低强度预处理下各组GRFS和CRFS均显著劣于单倍体组。

核心结论

  • 作者认为数据支持清髓移植使用脐血、7/8骨髓或联合血清治疗的7/8外周血移植物,减低强度移植使用单倍体移植物。
  • 单倍体组在所有组中GRFS、CRFS和总生存最佳。

研究设计与样本

  • 注册回顾性分析,纳入2198例接受替代供者造血干细胞移植的患者:脐血838例、单倍体159例、7/8骨髓241例、7/8外周血960例。
  • 各组按清髓预处理或减低强度预处理划分,单倍体组多数接受减低强度预处理。
  • 多变量分析以P<.0071、直接两两比较以P<.00025为统计学显著。

主要发现

  • 多变量分析中单倍体组GRFS、CRFS和总生存最佳。
  • 清髓预处理下脐血、7/8骨髓与联合血清治疗(阿仑单抗或抗胸腺细胞球蛋白)的7/8外周血组间GRFS和CRFS无差异。
  • 清髓预处理下7/8外周血未联合血清治疗组较7/8骨髓组GRFS显著更差、慢性GVHD更高、CRFS有更差趋势(HR 1.38,95%CI 1.13-1.69,P=.002)。
  • 清髓预处理下7/8外周血未联合血清治疗组较脐血组慢性GVHD更高、CRFS有更差趋势(HR 1.36,95%CI 1.14-1.63,P=.0006)。
  • 减低强度预处理下所有组GRFS和CRFS均显著劣于单倍体组。

关键数值与推荐

  • 多变量分析统计学显著性阈值P<.0071,直接两两比较阈值P<.00025。
  • 7/8外周血未联合血清治疗组 vs 7/8骨髓组:GRFS更差,慢性GVHD更高,CRFS趋势更差(HR 1.38,95%CI 1.13-1.69,P=.002)。
  • 7/8外周血未联合血清治疗组 vs 脐血组:慢性GVHD更高,CRFS趋势更差(HR 1.36,95%CI 1.14-1.63,P=.0006)。

临床怎么用

  • 作者认为清髓移植可选用脐血、7/8骨髓或联合血清治疗的7/8外周血移植物。
  • 作者认为减低强度移植可选用单倍体移植物。

局限性

  • 原文指出为注册回顾性分析。
  • 原文指出选择供者时可能存在中心选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is no consensus on the best choice of an alternative donor (umbilical cord blood [UCB], haploidentical, one-antigen mismatched [7/8]-bone marrow [BM], or 7/8-peripheral blood [PB]) for hematopoietic cell transplantation (HCT) for patients lacking an HLA-matched related or unrelated donor. METHODS: We report composite end points of graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) and chronic GVHD (cGVHD)-free relapse-free survival (CRFS) in 2,198 patients who underwent UCB (n = 838), haploidentical (n = 159), 7/8-BM (n = 241), or 7/8-PB (n = 960) HCT. All groups were divided by myeloablative conditioning (MAC) intensity or reduced intensity conditioning (RIC), except haploidentical group in which most received RIC. To account for multiple testing, P < .0071 in multivariable analysis and P < .00025 in direct pairwise comparisons were considered statistically significant. RESULTS: In multivariable analysis, haploidentical group had the best GRFS, CRFS, and overall survival (OS). In the direct pairwise comparison of other groups, among those who received MAC, there was no difference in GRFS or CRFS among UCB, 7/8-BM, and 7/8-PB with serotherapy (alemtuzumab or antithymocyte globulin) groups. In contrast, the 7/8-PB without serotherapy group had significantly inferior GRFS, higher cGVHD, and a trend toward worse CRFS (hazard ratio [HR], 1.38; 95% CI, 1.13 to 1.69; P = .002) than the 7/8-BM group and higher cGVHD and trend toward inferior CRFS (HR, 1.36; 95% CI, 1.14 to 1.63; P = .0006) than the UCB group. Among patients with RIC, all groups had significantly inferior GRFS and CRFS compared with the haploidentical group. CONCLUSION: Recognizing the limitations of a registry retrospective analysis and the possibility of center selection bias in choosing donors, our data support the use of UCB, 7/8-BM, or 7/8-PB (with serotherapy) grafts for patients undergoing MAC HCT and haploidentical grafts for patients undergoing RIC HCT. The haploidentical group had the best GRFS, CRFS, and OS of all groups.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Mehta RS, Holtan SG, Wang T, et al. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020. PMID: 32364845. doi:10.1200/JCO.19.00396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。